Abstract
Introduction Amid the global COVID-19 pandemic, vaccines were conditionally authorised for human use to protect against severe infection. The BRAVE toolkit, a user-friendly R Shiny application, was developed retrospectively together with the European Medicine Agency (EMA) with the aim of fulfilling the need for flexible tools to assess vaccine benefits and risks during and outside a pandemic situation.
Method This study employed BRAVE to evaluate the impact of COVID-19 mRNA vaccines across 30 EU/EEA countries by quantifying the number of prevented clinical events (i.e., confirmed infections, hospitalisations, intensive care unit (ICU) admissions, and deaths), using a probabilistic model informed by real-time incidence data and vaccine effectiveness estimates. The analysis assumes fixed population dynamics and behaviour. Additionally, BRAVE assesses risks associated with mRNA-based vaccines (myocarditis or pericarditis) by comparing observed incidence rates in vaccinated individuals with background incidence rates.
Results mRNA vaccines were estimated to directly prevent 11.150 million (95% Confidence Interval (CI): 10.876 – 11.345) confirmed COVID-19 infections, 0.739 million (95% CI: 0.727 – 0.744) COVID-19 hospitalisations, 0.107 million (95% CI: 0.104 – 0.109) ICU admissions, and 0.187 million (95% CI: 0.182 – 0.189) COVID-19-related deaths in the EU/EEA between 13 December 2020 and 31 December 2021. Despite increased vaccination-associated myocarditis or pericarditis observed in younger men, the benefits of vaccination still outweigh these risks.
Conclusion Our study supports the benefit/risk profile of COVID-19 vaccines and emphasises the utility of employing a flexible toolkit to assess risks and benefits of vaccination. This user-friendly and adaptable toolkit can serve as a blueprint for similar tools, enhancing preparedness for future public health crises.
Competing Interest Statement
HGD, DRM, CC, XK and CQ were employees of the European Medicines Agency at the time of elaboration of this work and have no conflict of interest. HGD is a co-founder and holds stock options in Rynd Biotech, a startup company for the rapid detection of sexually transmitted infections. NH holds a grant sponsored by MSD, Janssen Vaccines & Prevention, GSK (Glaxo SmithKline), and has received consulting fees for his participation in the advisory board for Janssen Global Services, and payment for expert testimony for MSD. LW and SA are PIs of a research project on COVID-19 modelling funded by the Research Foundation; Flanders (FWO Belgium, G059423N). GM declares its participation on a data safety monitoring board or advisory board for COVID-19 vaccine trials of Janssen Pharmaceutica. These potential conflicts of interest have not influenced the design, conduct, or reporting of the work presented in this manuscript. All other authors declare no competing interests.
Funding Statement
This work received funding from the European Medicines Agency under the framework service contract EMA/2017/09/PE (lot 1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Target journal: Eurosurveillance.
Data Availability
The default datasets can be accessed in the BRAVE toolkit. The full study protocol and report related to this study can be consulted at EUPAS4429. Upon request to the authors, the source code behind the BRAVE toolkit can be provided.
